How sham patents are hurting the pharma industry
The FTC is cracking down on pharma companies filing sham patents in the Orange Book to delay generics competition.
The FTC is cracking down on pharma companies filing sham patents in the Orange Book to delay generics competition.
Countries such as Australia have already ceased the supply of Vaxzevria, with its use discontinued since March 2023.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
GSK, Lundbeck, ROVI: Three Journeys of Unified Pharma Events Management
NIH team develops AI tool to predict cancer drug response
TetraScience and Google Cloud link for AI-driven drug developments
Bayer and Google Cloud to develop AI solutions for radiologists